ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Drugs and Targets: FDA approves Velcade in mantle cell lymphoma

October 17, 2014

Funding Opportunity: Leukemia & Lymphoma Society Launches Myeloid Program

October 31, 2014

In Brief: Day, Foti Lead Coalition; Harkin Ends Campaigns; UT Southwestern Recieves $85 Mil. In Donations

March 13, 1992

In Brief: ASCO Letter To Clinton Urges support For Trials; Senator Praises NCI, Bristol; Berlin Back A NCI

January 15, 1993

Wilding named director, Univ. of Wisconsin Cancer Center.

January 30, 2004

NCI Advisory Group, Other Cancer Meetings for Oct., Nov., Future

September 29, 1989